Immunic, Inc. (NASDAQ:IMUX) Given Average Rating of “Buy” by Brokerages

Immunic, Inc. (NASDAQ:IMUX) has earned an average rating of “Buy” from the seven research firms that are presently covering the stock, Marketbeat reports. Five research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 1 year price objective among analysts that have covered the stock in the last year is $11.80.

A number of equities analysts have commented on IMUX shares. HC Wainwright initiated coverage on shares of Immunic in a research report on Monday. They issued a “buy” rating and a $10.00 price target on the stock. Leerink Partners reaffirmed an “outperform” rating and set a $5.00 price target on shares of Immunic in a report on Monday, September 9th. B. Riley initiated coverage on Immunic in a research report on Tuesday, August 27th. They issued a “buy” rating and a $6.00 price objective for the company. Leerink Partnrs upgraded Immunic to a “strong-buy” rating in a report on Monday, September 9th. Finally, EF Hutton Acquisition Co. I raised Immunic to a “strong-buy” rating in a report on Monday, September 16th.

Immunic Stock Up 5.3 %

NASDAQ:IMUX opened at $1.20 on Friday. The firm has a 50-day moving average price of $1.37 and a 200 day moving average price of $1.34. The firm has a market capitalization of $108.09 million, a PE ratio of -0.98 and a beta of 1.88. Immunic has a 12-month low of $0.97 and a 12-month high of $2.11.

Insider Transactions at Immunic

In related news, Director Richard Alan Rudick purchased 87,300 shares of the stock in a transaction on Tuesday, November 12th. The shares were purchased at an average price of $1.15 per share, with a total value of $100,395.00. Following the transaction, the director now directly owns 87,300 shares of the company’s stock, valued at $100,395. This trade represents a ? increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 3.00% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Immunic

Hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. lifted its position in shares of Immunic by 100.7% in the first quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company’s stock valued at $4,480,000 after buying an additional 1,703,047 shares during the last quarter. Janus Henderson Group PLC acquired a new stake in Immunic during the 1st quarter valued at $9,266,000. Ikarian Capital LLC boosted its position in Immunic by 258.3% during the first quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company’s stock worth $2,128,000 after purchasing an additional 1,162,378 shares during the period. Jane Street Group LLC increased its holdings in shares of Immunic by 121.4% in the third quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock valued at $116,000 after purchasing an additional 38,553 shares during the last quarter. Finally, State Street Corp raised its position in shares of Immunic by 7.5% in the third quarter. State Street Corp now owns 167,145 shares of the company’s stock valued at $276,000 after purchasing an additional 11,642 shares during the period. Institutional investors own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.